List view / Grid view
Investment into vaccines based on broadly neutralising antibodies could allow pan-virus vaccines to be developed and stockpiled before the next pandemic, say researchers.
Report finds 2020 was a record-breaking year for investment in UK biotech, driven by innovation and the COVID-19 pandemic, with growth anticipated to continue into 2021.
UK Prime Minister Boris Johnson has announced a £20 million investment fund for medicine manufacturing and supply chains in the UK.
According to the BIA, less than four percent of eligible projects received funding from a government programme for early-stage biotech companies.
Through the recent coronavirus crisis, the UK’s pharmaceutical sector has performed strongly and delivered innovation at a time when it was most needed. In this article, Dr Cheryl Teoh discusses how the industry has been set up for success.
The WHO has said that the Access to COVID-19 Tools Accelerator will receive almost $1 billion of funding to boost access to tests, treatments and vaccines.
Matt Hancock has announced that the £500 million investment will go towards new COVID-19 testing technologies and increased testing capacity.
The COVID-19 pandemic has had huge knock-on effects on economies around the world. In this article, legal experts from Taylor Wessing explore how the novel coronavirus has hit the life sciences and biotech investment sector and how they see investors behaving as the lockdown and pandemic eases and develops over…
Within this issue find articles on the complexities of sterility assurance, how to detect and eliminate the risk of NDMA contamination and the findings from a study involving a novel formulation of cannabinoids that has been developed to treat glioblastoma. Also included are articles on the opportunities blockchain provides for…
After "allegations of wrongdoing" were connected to Eastman Kodak Company following a $765 million loan from the US government, a review has been announced.
The National Institutes of Health in the US has awarded contracts to seven biomedical companies to develop and manufacture COVID-19 diagnostics.
The UKRI and NIHR will fund projects worth £4.3 million to investigate the disproportionate death rate from COVID-19 among people from BAME backgrounds.
Sandoz plans to invest €150 million and the Austrian government €50 million into integrated antibiotic manufacturing operations at Kundl.
The UK government has committed £100 million to establish a centre to scale up COVID-19 vaccine and gene therapy manufacturing.
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
